Temporal Changes in Adverse Events in the ENDURANCE Trial

被引：0
|
作者：
Milano, C. A. [1 ]
Pagani, F. D. [2 ]
Tatooles, A. J. [3 ]
Mokadam, N. A. [4 ]
Miller, J. [5 ]
Wozniak, T. C. [6 ]
Selzman, C. H. [7 ]
Leadley, K. [8 ]
Aaronson, K. D. [2 ]
Rogers, J. G. [9 ]
机构：
[1] Duke Univ, Sch Med, Dept Surg, Durham, NC USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Advocate Christ Med Ctr, Oak Lawn, IL USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Emory Healthcare, Atlanta, GA USA
[6] Indiana Univ Hlth, Indianapolis, IN USA
[7] Univ Utah, Salt Lake City, UT USA
[8] HeartWare, Framingham, MA USA
[9] Duke Univ, Sch Med, Durham, NC USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2016年 / 35卷 / 04期
关键词：
D O I：
10.1016/j.healun.2016.01.025
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2
引用
收藏
页码：S9 / S9
页数：1
相关论文
共 50 条
  • [21] Changes in plasma taurine levels after different endurance events
    Ward, RJ
    Francaux, M
    Cuisinier, C
    Sturbois, X
    De Witte, P
    AMINO ACIDS, 1999, 16 (01) : 71 - 77
  • [22] Reduction in major adverse limb events in the COMPASS trial
    Lim, Gregory B.
    NATURE REVIEWS CARDIOLOGY, 2018, 15 (05) : 255 - 255
  • [23] Variability in the assessment of adverse events in a multicenter clinical trial
    Raisch, DW
    Troutman, WG
    Sather, MR
    Fudala, PJ
    CLINICAL THERAPEUTICS, 2001, 23 (12) : 2011 - 2020
  • [24] Reduction in major adverse limb events in the COMPASS trial
    Gregory B. Lim
    Nature Reviews Cardiology, 2018, 15 : 255 - 255
  • [25] The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial
    Michael T. Eadon
    Marc B. Rosenman
    Pengyue Zhang
    Cathy R. Fulton
    John T. Callaghan
    Ann M. Holmes
    Kenneth D. Levy
    Samir K. Gupta
    David M. Haas
    Raj Vuppalanchi
    Eric A. Benson
    Rolf P. Kreutz
    Emma M. Tillman
    Tyler Shugg
    Rebecca C. Pierson
    Brandon T. Gufford
    Victoria M. Pratt
    Yong Zang
    Zeruesenay Desta
    Paul R. Dexter
    Todd C. Skaar
    The Pharmacogenomics Journal, 2023, 23 (6) : 169 - 177
  • [26] The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial
    Eadon, Michael T.
    Rosenman, Marc B.
    Zhang, Pengyue
    Fulton, Cathy R.
    Callaghan, John T.
    Holmes, Ann M.
    Levy, Kenneth D.
    Gupta, Samir K.
    Haas, David M.
    Vuppalanchi, Raj
    Benson, Eric A.
    Kreutz, Rolf P.
    Tillman, Emma M.
    Shugg, Tyler
    Pierson, Rebecca C.
    Gufford, Brandon T.
    Pratt, Victoria M.
    Zang, Yong
    Desta, Zeruesenay
    Dexter, Paul R.
    Skaar, Todd C.
    PHARMACOGENOMICS JOURNAL, 2023, 23 (06): : 169 - 177
  • [27] Recent changes to clinical trial regulation in India: Focus on serious adverse events, compensation and registration of ethics committees
    Karwa M.
    Arora S.
    Agrawal S.G.
    Pharmaceutical Medicine, 2013, 27 (5) : 283 - 288
  • [28] Major adverse cardiac events in the ESPS-2 trial
    Diener, HC
    Darius, H
    Betrand-Hardy, JM
    Humphreys, M
    STROKE, 2000, 31 (11) : 2868 - 2868
  • [29] Inquiry into adverse events in trial blames drug, not study design
    Mayor, S
    BRITISH MEDICAL JOURNAL, 2006, 332 (7546): : 870 - 870
  • [30] Endurance Sporting Events
    Golubjatnikov, Matt
    Walker, Anne
    EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2024, 42 (03) : 581 - 596
12345